Clinical trial · Observational
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
Prospective Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
to determine the values of imaging and genetic biomarkers for prediction of tumor aggressiveness and prognosis in patient with early stage lung adenocarcinoma to Identify unique copy number alteration in patient with early stage lung adenocarcinoma to evaluate the long-term change of ground-glass nodule combined with lung adenocarcinoma to suggest a guideline for planning an appropriate follow-up examination and management
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT, PET, copy number alteration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- early stage lung adenocarcinoma
- interventionNames
- Other: CT, PET, copy number alteration
Primary outcomes (1)
- measure
- Prediction of tumor aggressiveness
- timeFrame
- five years
Secondary outcomes (1)
- measure
- prognosis of early stage lung adenocarcinoma following operation
- timeFrame
- five years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * A. Clinically and radiologically suspected lung adenocarcinoma * B. Newly-diagnosed Stage I or II from the clinical work up including PET/CT * C. Performance status of 0 to 1 on the ECOG scale * D. Age 20 years or older * E. Able to tolerable DECT imaging required by protocol * F. Able to give study-specific informed consent Exclusion Criteria: * A. Prior malignancy * B. planning of Definitive RTx 나 neoadjuvant CCRTx * C. Poor cardiopulmonary reserve
References
Publications (0)
Data not yet available